Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: lucas pc. Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
Residential exposure to traffic pollution and mammographic density in premenopausal women.
Jiménez T, Domínguez-Castillo A, Fernández de Larrea-Baz N, Lucas P, Sierra MÁ, Salas-Trejo D, Llobet R, Martínez I, Pino MN, Martínez-Cortés M, Pérez-Gómez B, Pollán M, Lope V, García-Pérez J. Jiménez T, et al. Among authors: lucas p. Sci Total Environ. 2024 Apr 12;928:172463. doi: 10.1016/j.scitotenv.2024.172463. Online ahead of print. Sci Total Environ. 2024. PMID: 38615764
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA. Fernandez-Martinez A, et al. Among authors: lucas pc. JAMA Oncol. 2024 Mar 28:e237304. doi: 10.1001/jamaoncol.2023.7304. Online ahead of print. JAMA Oncol. 2024. PMID: 38546612 Free PMC article.
Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial).
Guinot PG, Desebbe O, Besch G, Guerci P, Gaudard P, Lena D, Mertes PM, Abou-Arab O, Bouhemad B; NOVACC study group. Guinot PG, et al. Am Heart J. 2024 Mar 16;272:86-95. doi: 10.1016/j.ahj.2024.03.008. Online ahead of print. Am Heart J. 2024. PMID: 38492626 Free article.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Mamounas EP, et al. Among authors: lucas pc. Clin Cancer Res. 2024 Feb 20. doi: 10.1158/1078-0432.CCR-23-1977. Online ahead of print. Clin Cancer Res. 2024. PMID: 38376912
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Chen L, Wang Y, Cai C, Ding Y, Kim RS, Lipchik C, Gavin PG, Yothers G, Allegra CJ, Petrelli NJ, Suga JM, Hopkins JO, Saito NG, Evans T, Jujjavarapu S, Wolmark N, Lucas PC, Paik S, Sun M, Pogue-Geile KL, Lu X. Chen L, et al. Among authors: lucas pc. J Clin Oncol. 2024 May 1;42(13):1520-1530. doi: 10.1200/JCO.23.01080. Epub 2024 Feb 5. J Clin Oncol. 2024. PMID: 38315963
1,118 results